Quantcast

Entelos Closes Funding Round for Growth

June 20, 2013

Provider of predictive physiological simulations continues to transform modeling and simulation.

San Mateo, CA (PRWEB) June 20, 2013

Entelos, a premier provider of physiological systems modeling and services that help pharmaceutical and consumer product companies predict better paths to success, today announced that it has received additional financing from its current investors Clearlake Capital Partners (Clearlake) and Michaelson Capital Partners (Michaelson). The financing will support the company´s expansion and continued technology innovation.

“There´s a new Entelos out there. Entelos has transformed its business to support pharmaceutical companies and consumer goods companies embrace physiological modeling, and enable the internalization and creation of centers of physiological modeling excellence,” said Shawn O´Connor, CEO and President of Entelos. “We now support the customers’ physiological simulation investment journey providing tools, models and services to enable companies to make incremental investments along the journey from targeted models to full disease models that represent the patient population.”

Today´s funding demonstrates the continued support by existing investors Clearlake and Michaelson and provides the Company with additional capital necessary to continue its strategic alignment, product development and growth strategy. This funding supports the continued delivery of our unique in silico modeling and simulation products and consulting services that have helped companies reduce product pipeline risk and accelerate product success through improved insights and decision support.

Entelos is an in silico modeling and simulation software and services company, delivering predictive technologies reducing risk, time, and cost of product development for pharmaceutical, biotechnology, nutrition and consumer products customers. The Company’s PhysioLab systems biology platforms generate virtual patient populations, providing highly predictive analyses to develop safer and more effective drugs, foods and consumer products. Entelos´ understanding of patient variability has significant application to the emerging field of personalized medicine. The company is headquartered in San Mateo, California. For more information, please visit http://www.entelos.com.

Clearlake is a private investment firm focused on special situations private equity such as corporate divestitures, recapitalizations, buyouts, restructurings, turnarounds and other equity investments. Clearlake seeks to partner with world-class management teams by providing patient, long-term capital and operational expertise to invest in businesses going through change. Clearlake´s founding principals have led over 50 investments totaling more than $2.7 billion of capital in sectors including business services, communications and media, energy and power, healthcare, manufacturing, retail/consumer, and technology. For more information, please visit http://www.clearlakecapital.com .

Michaelson is a private investment firm that focuses on assisting great management teams to achieve their objectives. Founded in 2005, Michaelson provides growth capital to companies in the technology and healthcare sectors and invests in special situations including management buyouts and restructurings. The partners of Michaelson have led over 100 transactions totaling more than $2.0 billion. For more information, please visit http://www.michaelsoncapital.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/6/prweb10847440.htm


Source: prweb



comments powered by Disqus